A prospective longitudinal study was conducted to assess the Apo B100/A1 ratio as a marker of cardiovascular risk in children with epilepsy aged 5-14 years on long-term anti-seizure medication monotherapy with either sodium valproate, oxcarbazepine, or levetiracetam. Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
apo b100/a1
12
b100/a1 ratio
12
children epilepsy
8
monotherapy sodium
8
sodium valproate
8
valproate oxcarbazepine
8
oxcarbazepine levetiracetam
8
change apo
4
ratio children
4
epilepsy monotherapy
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!